Stay updated with breaking news from Dipal Doshi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]
BOSTON, May 16, 2024 -- Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]